Omzotirome

Omzotirome (INN), formerly codenamed TRC-150094, is a thyromimetic drug which acts as a metabolic modulator which restores metabolic flexibility. It has been shown to improve insulin resistance and hyperglycemia, and is in Phase III human clinical trials for the treatment of Cardiometabolic-Based Chronic Disease (CMBCD) by improving dysglycemia, dyslipidemia and hypertension.^{[1][2][3][4][5]}

Omzotirome

Identifiers
IUPAC name 3-(4-((7-Hydroxy-6-methyl-2,3-dihydro-1H-inden-4-YL)methyl)-3,5-dimethyl-1H-pyrazol-1-yl)propanoic acid
CAS Number	1092551-88-6
PubChem CID	25125529
DrugBank	DB16046
ChemSpider	28534873
UNII	B93608MTGW
ChEMBL	ChEMBL4297445
CompTox Dashboard (EPA)	DTXSID70148862
Chemical and physical data
Formula	C19H24N2O3
Molar mass	328.412 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=CC(=C2CCCC2=C1O)CC3=C(N(N=C3C)CCC(=O)O)C
InChI InChI=1S/C19H24N2O3/c1-11-9-14(15-5-4-6-16(15)19(11)24)10-17-12(2)20-21(13(17)3)8-7-18(22)23/h9,24H,4-8,10H2,1-3H3,(H,22,23) Key:OFUOCIUIWKDKPA-UHFFFAOYSA-N